Brokerages Set Lantheus Holdings, Inc. (NASDAQ:LNTH) Target Price at $129.43

Lantheus Holdings, Inc. (NASDAQ:LNTH) has been assigned a consensus rating of “Buy” from the seven research firms that are presently covering the stock, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $129.43.

LNTH has been the topic of several analyst reports. The Goldman Sachs Group assumed coverage on Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target on the stock. B. Riley dropped their target price on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. JMP Securities reiterated a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. Finally, Truist Financial increased their price objective on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research note on Thursday, February 27th.

Lantheus Stock Up 0.3 %

NASDAQ:LNTH opened at $97.93 on Friday. The stock has a market capitalization of $6.71 billion, a price-to-earnings ratio of 16.29 and a beta of 0.38. Lantheus has a 52 week low of $58.16 and a 52 week high of $126.89. The firm has a 50 day moving average of $93.41 and a 200 day moving average of $96.28.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. As a group, analysts expect that Lantheus will post 6.01 EPS for the current year.

Insider Activity at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares of the company’s stock, valued at approximately $11,445,207.20. This trade represents a 8.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 64,109 shares of company stock valued at $6,110,806 over the last three months. 1.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Lantheus

Large investors have recently made changes to their positions in the stock. Janus Henderson Group PLC raised its holdings in shares of Lantheus by 72.7% in the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider’s stock worth $554,583,000 after acquiring an additional 2,610,118 shares during the last quarter. Farallon Capital Management LLC increased its position in shares of Lantheus by 79.9% in the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock worth $475,590,000 after acquiring an additional 2,361,000 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its position in Lantheus by 40.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock worth $135,025,000 after acquiring an additional 435,445 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Lantheus in the 4th quarter valued at about $36,183,000. Finally, Groupama Asset Managment acquired a new stake in shares of Lantheus during the third quarter worth approximately $439,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.